Epigenetic therapy in myeloproliferative neoplasms: evidence and perspectives.

The myeloproliferative neoplasms The molecular pathogenesls of MPN Epigenetic events In cancer Epigenetic events In MPN Drugs for epigenetic therapy Epigenetic therapy In MPN Conclusions

The myeloproliferative neoplasms

According to the 2008 classification system for haematologic malignancies from the World Health Organization (WHO) the category of myeloproliferative neoplasms (MPNs) includes chronic myelogenous leukaemia (CML, which is marked by the t(9;22)(q34;q11) translocation- BCR/ABL rearrangement), polycythaemia vera (PV), essential thrombocythaemia (ET), primary myelofibrosis (PMF), mastocytosis, chronic eosinophilic leukaemia not otherwise specified (CEL-NOS), chronic neutrophilic leukaemia (CNL) and ‘MPN, unclassifiable’[ 1 ]. In this review, we will focus only on the so-called ‘classic’ MPNs, that is PV, ET and PMF, with reference to other MPNs if appropriate. These disorders, whose original identification is credited to W. Dameshek in 1951 [ 2 ], share a number of common features [ 3 ] that include: the origin in a multi-potent haematopoietic stem cell; an expanded pool of mature cells and precursors with preserved cellular maturation; discrete overlap in the clinical phenotype, and the possibility to transform each into the other or to evolve to acute myeloid leukaemia (AML) [ 4 ]. A revision [ 5 ] to the previous 2001 WHO classification has been prompted by discoveries in 2005 of recurrent mutations in janus kinase 2 (JAK2; JAK2V617F) [ 6 – 9 ] or MPL (MPLW515L/K) [ 10 ] and of JAK2 exon 12 mutations [ 11 ], which have rapidly improved knowledge on pathogenetic aspects of the diseases and simplified the diagnostic approach. Several recent reviews on these issues have been published [ 12 – 16 ].

PV and ET are relatively indolent disorders [ 17 ] that result in a modest reduction of survival, particularly evident after the first decade far from diagnosis; on the contrary, PMF has a more severe course with median survival of about 5 years, although younger patients with low-risk disease may experience survival in excess of 10 years. The most clinically relevant events that occur during the course of PV or ET are arterial and venous thrombosis, haemorrhage, evolution to post-polycythemic or post-thrombocythemic myelofibrosis [ 18 ] and transformation to AML [ 19 – 21 ]. In the observational arm of the European collaborative study on low-dose aspirin in PV (ECLAP), the largest study available that included 1638 patients, thrombotic events and transformation to myelofibrosis or AML were responsible for 41% and 13% of all fatalities [ 20 , 22 ]; accordingly, patients with PV or ET are currently stratified according to the risk of cardiovascular events [ 23 ]. Age older than 60 years and/or a previous history of thrombosis allow to identify a category of patients with ‘high-risk’ disease who, unlike the others, are candidate to cytoreductive therapy [ 20 , 24 , 25 ]; in addition, low-dose aspirin is recommended in all PV patients independent of risk category [ 26 ] as well as in most patients with ET. The most commonly used cytoreductive agent is hydroxyurea (HU) because of its proven effectiveness in reducing life-threatening cardiovascular events [ 27 – 29 ]. However, the safety of HU as concerns the risk of transformation to acute leukaemia is still an unsettled issue [ 16 , 23 ], although most evidence are against a significant raised rate of occurrence [ 22 ]. On the other hand, the risk of leukaemia was significantly increased in patients who received other chemotherapeutics in combination or in sequence with HU [ 22 , 30 ], or who were treated with radiophosphorus [ 22 ] or chlorambucil [ 31 ].

In patients with PMF, the major causes of death are represented by portal hypertension or hepatic/splenoportal thrombosis and their complications, heart failure, infections, pulmonary hypertension, bleeding, thromboses and leukaemia transformation [ 21 , 32 ]. Patients with low- and high-risk disease with significantly different survival can be identified based on prognostic scoring systems [ 33 , 34 ]. Stratification according to the risk is particularly relevant for younger patients who can potentially exploit the curative effect of allogeneic haematopoietic stem cell transplantation [ 35 ]; in fact, conventional drug therapy does not appreciably modify the course of disease and it is reserved to patients who present anaemia or have symptomatic splenomegaly.

In summary, therapy for MPNs is mainly employed to counteract signs and symptoms of myeloproliferation, to prevent thrombosis and for the treatment of anaemia or thrombocytopenia in myelofibrosis; however, with the possible exception of interferon-α (IFN-α) in PV according to recent reports [ 36 – 38 ], none of the agents currently employed proved able to significantly affect the abnormally proliferating myeloid clone.

The molecular pathogenesis of MPN

The first recurrent molecular abnormalities in the classic MPN have been identified only a few years ago. The JAK2V617F mutation, as a result of a G to T nucleotide shift at nt 1849 in exon 14, is located in the tyrosine kinase-like domain-2 (JH2) pseudo-kinase domain of JAK2 and likely results in the loss of auto-inhibitory control and/or cytokine-induced hyper-activation of JAK2 [ 39 ]. Expression of V617F-mutated allele in cytokine-dependent cell lines conferred cytokine independence and cytokine hypersensitivity through the constitutive activation of signal transducers and activators of transcription-5 (STAT5), v-akt murine thymoma viral oncogene homolog 1 (AKT) and extracellular signal-regulated kinase (ERK)-dependent pathways [ 13 , 40 ]; in addition, mice transplanted with marrow cells transduced with a retrovirus expressing JAK2V617F invariably developed erythrocytosis [ 6 , 41 – 44 ] eventually associated with leucocytosis, splenomegaly and later changes suggestive of transformation to post-polycythemic myelofibrosis [ 41 – 44 ]. More recently, transgenic mice presenting an expression of mutated allele lower than wild-type one have been generated, and found to develop an ET-like phenotype [ 45 , 46 ]; overall these data suggest that the JAK2V617F mutation is an integral component of the myeloproliferative process that underlies the different classic MPNs. The frequency of JAK2V617F mutation is estimated at over 95% in PV, 60% in ET or PMF [ 47 , 48 ] as well as >50% in patients with the infrequent entity ‘refractory anaemia with ringed sideroblasts and thrombocytosis’ (RARS-T) [ 49 , 50 ]. The mutation can be found on one or both alleles (homozygosity) as a result of a mitotic recombination process that occurs in most patients with PV or PMF and a minority only of ET [ 6 , 8 , 9 ]. Additional complex mutations, deletions or insertions have been detected in exon 12 of JAK2 and are usually associated with clinical features typical of a JAK2V617F-negative PV or idiopathic erythrocytosis [ 11 , 51 ]. Finally, somatic mutations involving codon 515 of MPL [ 10 , 52 ] (the receptor for thrombopoietin, named after myeloproliferative leukaemia virus oncogene homologue) are located in the cytoplasmic juxtamembrane portion; the commonest are represented by W515L (a tryptophan to leucine substitution) and W515K (a tryptophan to lysine substitution). They are detected in ≅10% of patients with PMF [ 10 , 52 , 53 ] or ≅8% of JAK2V617F-negative ET [ 54 , 55 ]. MPLW515L introduction in cell lines resulted in a cytokine-independent growth and hyper-sensitivity to thrombopoietin [ 56 ], while its expression in a transplant murine model caused a rapidly fatal disease reminiscent of PMF [ 10 ]. Interestingly, in some patients multiple MPL mutations or the coexistence with JAK2V617F allele have been reported [ 53 , 55 , 57 ].

There are some hypotheses to explain the association of JAK2V617F mutation with at least three different clinical phenotypes [ 58 , 59 ]. One is the so-called ‘gene-dosage’ hypothesis that suggests that disease-associated phenotypes are the result of the relative proportion of mutated and wild-type allele, with ET (the lowest) and PV or post-polycythemic myelofibrosis (the highest) located at the opposite of the spectrum. Second, JAK2V617F may not be the initial clonogenic event in MPNs and a predicted ‘pre- JAK2 ’ mutated cell exists as the founder of clonal haematopoiesis that acquires JAK2 mutation as a secondary event [ 60 , 61 ]. This hypothesis is also supported by recent findings of mutations in ten-eleven translocation-2 (TET-2) reported by the Vainchenker's group [ 62 ]. Finally, there can be a role also for inherited host genetic characteristics, such as the single nucleotide polymorphisms (SNPs) in JAK2 that have been associated preferentially with the diagnosis of PV rather than the other MPNs [ 63 ], or generic host characteristics (gender, iron availability, hormones). Furthermore, it can be suggested that subtle changes in gene expression because of epigenetic regulation also contribute, in a non-mutually exclusive but rather cooperative manner with the previous events, to the MPN phenotypic variability. After all, it is a matter of speculation if PV, ET and PMF are separate diseases or different presentations/different phases of a unique disease [ 64 ].

Epigenetic events in cancer

Epigenetic changes are cell-heritable, potentially modifiable abnormalities that affect gene expression [ 65 ]. There are two main classic mechanisms that control gene expression through epigenetic changes: DNA methylation and acetylation of histone proteins. However, although most efforts in understanding epigenetics and in developing epigenetic therapy have been directed against DNA methylation and histone acetylation, additional epigenetic alterations are probably at least as relevant as the previous two; these include histone methylation that can be associated either with transcriptional activation or repression [ 66 , 67 ], or other key molecules involved in the regulation of gene expression, such as micro-ribonucleic acids (microRNAs) [ 68 ] ( Fig. 1 ).

DNA methylation occurs when a cytosine residue at a ‘CpG’ site, that is a cytosine that precedes a guanine, becomes covalently bound with a methyl group at the 5-carbon position, a reaction that is catalyzed by a family of DNA methyltransferases. There are CpG dinucleotide-rich regions in specific locations along the genome that are called ‘CpG islands’, usually at the 5’ regulatory region of many genes; when there is a high degree of methylation in this CpG-rich regions of promoter, the gene cannot be efficiently transcribed. Promoter methylation is a normal process for the orchestrated control of transcriptional activity during development and cell-lineage specification, but it also contributes substantially to tumourigenesis. Hypermethylation at specific gene loci, particularly of tumour-suppressor genes, and global hypomethylation of genomic DNA, as well as inactivation of microRNA genes by DNA methylation [ 69 , 70 ], are all common findings in human cancer cells [ 69 – 71 ]. Reduced global methylation in cancer cells is mainly because hypomethylation of DNA repetitive sequences, coding regions and introns, particularly in areas of the genome characterized by a low content of coding genes, and increases further during cancer progression [ 72 ]. Mitotic recombination and chromosomal rearrangements can be facilitated by global DNA hypomethylation [ 73 ], as suggested by the observation that mice carrying a diffuse genome hypomethylation as a result of a hypomorphic DNA methyltransferase 1 (DNMT1) allele develop aggressive T-cell lymphomas associated with a high rate of chromosome 15 trisomy [ 74 ] and by the profound structural alterations of chromosome pericentromeric regions in the rare ‘immunodeficiency-centromeric instability-facial anomalies (ICF)’ syndrome (OMIM 242860) caused by germ-line mutations in DNMT3b [ 75 ]. Loss of methylation in normally silent regions of the genome could also cause the inappropriate expression of genes normally silenced, including imprinted genes or genes of the inactive X chromosome. On the opposite, abnormal gain in DNA methylation with aberrant silencing of transcription may occur at specific gene promoter regions and represents a mechanism for inactivation of tumour-suppressor genes. Examples are the hypermethylation of von Hippel Lindau gene in renal cancers or the cell-cycle control gene p16 in many types of cancer [ 76 ]. A tumour type-specific ‘hypermethyloma’ corresponds to the profile of CpG island hypermethylation in both sporadic cancers and inherited cancer syndromes; in the latter, occurring of abnormal methylation can be considered as the second lesion in a multiplehit tumourigenesis model [ 77 ]. The mechanistic relevance of gene promoter hypermethylation in genes that do not apparently function as tumour-suppressor genes is a matter of discussion, but it is very likely that these might contribute to the phenotypic diversity of cancer; for example, promoter hypermethylation-induced silencing of tissue inhibitor of metalloproteinases-3 (TIMP-3), which encodes for a protease inhibitor, may result in facilitation of tumour cell dissemination [ 78 ].

Hypermethylation of CpG islands in gene promoter regions is often associated with specific modification of histones; however, in some instances gene silencing in association with modified histone profile has been observed even in the absence of CpG island hypermethylation. As a matter of fact, differential chemical modifications of histone tail, that is acetylation and methylation, can affect not only DNA replication and DNA repair, but also gene transcription. Acetylation of histones is accomplished by the competing activities of histone acetyl transferase (HAT) and histone deacetylases (HDAC). Acetylated histones have a reduced interaction with the negatively charged DNA, because of lowered positive charge of lysine residue in the presence of acetyl group, and on turn this facilitates the interaction of transcription factors to consensus target sequences on gene promoter [ 79 ]. However, although drugs acting as HDAC inhibitors can facilitate the re-expression of genes whose promoter sequence is not hyperme-thylated, they are generally little or not effective in contrasting gene silencing when gene regulatory sequences are hypermethy-lated. A sequential treatment scheduling, which involves exposure to a demethylating agent followed by HDAC inhibitors, usually results in synergistic re-expression of silenced genes, at least in most culture conditions [ 80 ].

Mature microRNAs are short (19–25 nucleotides) RNAs originated from the cleavage of a 70–100 nucleotide hairpin precursor (pre-microRNA) that hybridize to complementary mRNA targets and either lead to their degradation or prevent their translation of corresponding protein, at least in part depending on the degree of nucleotide complementarity [ 81 – 83 ]. Expression of microRNAs is tissue and developmental stage specific, and as such they are involved in normal cell homeostasis; however, they are also being increasingly recognized as a new class of genes that are altered in human malignancies and can eventually function as oncogenes (onco-microRNAs) [ 84 ]. On the contrary, some microRNAs may have tumour-suppressor function, as argue by their down-regulation in certain tumours; for example let-7 and mir15/mir-16 control the expression of ras sarcoma (RAS) [ 85 ] and B cell lymphoma gene-2 (BCL-2) [ 86 ], respectively. A role of microRNAs in haematologic malignancies is supported by recent studies, and they have also been proposed as prognostic markers and therapeutic targets in chronic and acute leukaemias [ 87 ]. However, the fine mechanisms that tune the transcriptional expression of microRNAs are still largely unknown, and may depend on the binding of transcription factors to promoter [ 88 , 89 ] as well as on differential methylation of the microRNA gene or of putative 5’ regulatory sequences [ 90 , 91 ]. In turn, recent evidence suggests that miRNAs could also play important roles in controlling DNA methylation and histone modification [ 92 ].

Epigenetic events in MPN

Studies on epigenetic gene regulation in MPNs are still scanty and have been focused on single genes credited as being potentially involved in the pathogenesis of these disorders. Table 1 lists published studies that reported an analysis of gene methylation in cells from MPN patients; in most instances, no evidence for abnormal hypermethylation of the genes was found, while some notable exceptions will be discussed briefly here. Preliminary results of genome-wide methylation analysis pointed to a high rate of gene methylation in PMF patients [ 93 ]; furthermore, a unique profile of enhanced histone deacetylase enzyme activity has been described in these patients [ 94 ].

Much attention has been devoted to the study of gene methylation status of suppressors of cytokine signalling family proteins (SOCS), particularly SOCS1 and SOCS3. These proteins are rapidly induced following receptor binding of several cytokines, including erythropoietin, interleukin-3 (IL-3) and GM-CSF; in turn, they function as negative regulators of the JAK/STAT pathway by reducing the phosphorylation of both JAK and STAT, preventing STAT dimerization and its translocation to the nucleus, and finally resulting in reduced transcription of target genes [ 95 ]. Interestingly, the negative regulatory function of SOCS3 may be lost in MPN cells, because SOCS3 was actually found to be promoting, rather than reducing, the proliferation of cells expressing JAK2V617F, possibly through a JAK2V617F-induced enhanced phosphorylation of the protein itself [ 96 ]. Previous data indicated that SOCS1 can function as a tumour-suppressor gene and its down-regulation contributes to tumour progression [ 97 ]; SOCS1 down-regulation as a result of gene hypermethylation was detected in several neoplasia, including CML [ 98 ] where it corre-lated with poor cytogenetic response to IFN-α[ 99 ]. Similarly, hypermethylation of SOCS3 promoter with reduced protein levels was described in several solid tumours. Hypermethylation of SOCS3 in MPNs has been detected in several studies [ 100 – 103 ], particularly in PMF patients [ 103 ]; unexplainably, promoter methylation did not correlate with a low level of transcription, although a trend towards an association between SOCS3 methylation and reduced protein was observed in the subgroup of JAK2V617F-negative patients [ 101 ]. Of interest, SOCS3 hypermethylation was also detected in six ET females negative for the JAK2V617F or MPLW515L/K mutation who had clonal haematopoiesis [ 100 ]. Results concerning SOCS1 methylation have been more conflicting, and may largely depend on the genomic region employed for methylation status analysis. SOCS1 hypermethylation has been variably reported in AML [ 104 , 105 ], CML [ 98 , 106 ] and myelodysplastic syndromes [ 107 ]. Conversely, a minority only of MPN patients were reported to have SOCS1 hypermethylation [ 102 , 108 ].

Abnormally high levels of the polycythaemia rubra vera-1 (PRV-1) gene, encoding for the GPI-linked CD177 protein, are expressed by MPN neutrophils [ 109 ], although the levels of mature protein do not differ at all compared to control neutrophils. PRV-1 expression in PV or ET patients has been associated with a reduced level of methylation of CpG sites located close to the transcription start site [ 110 ], and decitabine decreased PRV-1 methylation and increased PRV-1 mRNA levels in the KG1 and KG1a leukaemic cell lines. Interestingly, methylation of PRV-1 correlated inversely with the presence of JAK2V617F mutation, and the degree of methylation at CpG 30 (the most conserved site of methylation in PRV-1 up-stream sequence) showed a significant inverse correlation with JAK2V617F allele burden [ 110 ].

The constitutive mobilization of haematopoietic stem CD34 + cells in the peripheral blood is a characteristic finding in patients with PMF [ 111 ]; the abnormally high number of circulating CD34 + cells has been associated with reduced membrane expression of C-X-C chemokine receptor type 4 (CXCR4), which is the receptor for stromal-derived factor-1 (SDF-1), the major chemoattractant for normal haematopoietic stem and progenitor cells [ 112 , 113 ]. It has been found that CXCR4 is epigenetically regulated and that the extent of methylation of unique CpG islands of the promoter is abnormally high in PMF compared to control cells and is correlated with the protein content on cell membrane [ 114 ]. A short-term treatment with 5-Aza reduced promoter methylation, increased membrane expression of CXCR4 and resulted in improved migration of CD34 + cells in response to SDF-1 in vitro [ 114 ]. Similar findings have been reported after long-term incubation of PMF CD34 + cells exposed to 5-Aza followed by trichostain A [ 115 ], and this treatment corrected bone marrow seeding of treated cells once infused in non-obese diabetic severe combined immunodeficiency (NOD/SCID) mice [ 116 ]. Importantly, it was shown that this combined treatment also caused reduced proliferation of PMF CD34 + (as opposite to normal cells) and resulted in significant reduction in the proportion of JAK2V617F mutated cells and of mutated cells harbouring the mutation in an homozygous status, suggesting a preferential effect on cells of the mutated clone [ 115 ].

How somatic mutations and abnormal epigenetic gene regulation interact in the pathophysiology of MPNs is largely unknown, but recent data lend support to suggesting a functional link between the increased tyrosine kinase activity of JAK2 and epigenetically regulated genes. Over-activation of the Hopscotch gene, a JAK homologue gene in Drosophila Melanogaster , led to a global disruption of heterochromatic gene silencing and promoted tumourigenesis, indicating that the JAK/STAT pathway normally regulates cellular epigenetic status [ 117 ]. Consistently, binding of STAT3 to promoter and enhancer sequences of the DNA methyltransferase 1 gene (DNMT1) in malignant T-cell lymphoma cells resulted in induction of DNMT1 expression, which in turn supported STAT3 persistent activation [ 118 ]. Overall, these data provided a framework for supporting a direct involvement of aberrant JAK/STAT signalling in epigenetic silencing of genes important for cellular transformation.

Finally, unique expression profiles of microRNAs in granulocytes [ 119 ] or other mature haematopoietic cell sub-populations [ 120 , 121 ] from MPN patients have been characterized; a general down-regulation of microRNAs was found, as reported in other cancer cells, with some notable exception of microRNAs that were overexpressed, some of them in a JAK2V617F-associated manner [ 119 , 120 ]. However, information about validated gene targets and the mechanisms underlying differential expression of microRNA in MPNs is still lacking [ 59 ].

Drugs for epigenetic therapy

Drugs acting on epigenetic control of gene expression fall into two broad categories: inhibitors of methyltransferases and histone deacetylase (HDAC) inhibitors (listed in Table 2 ). Among them, those most widely employed are azacytidine, decitabine and vorinostat. These drugs have been used in phase I trials in patients with haematological and solid cancers, and several phase II trials are underway ( Table 2 ). Among myeloid malignancies, most experience has been collected in patients with myelodysplastic syndromes and AML [ 122 ].

Hypomethylating agents such as azacitidine and decitabine act by inhibiting DNMT1 and cause DNA hypomethylation leading to induction of silenced genes involved in cellular differentiation and proliferation. Although the demethylating effect depends on incorporation of the drug into DNA, the cytotoxicity of azacitidine is additionally as a result of halting of protein synthesis because the drug is incorporated into RNA as well. Their clinical efficacy in haematological malignancies has been demonstrated in vitro and in a series of phase I and II trials. Azacitidine was first approved by FDA in 2004 for the treatment of myelodyspalstic syndrome (MDS), based on two phase II [cancer and leukemia group B (CALGB) 8421 and 8921] and one phase III (CALGB 9221) trials in which azacitidine at 75 mg/m 2 /day for 7 days every 28 days used by continuous intravenous infusion or subcutaneous administration was compared with the best supportive care. The phase II trials recorded complete remission (CR), partial remission (PR) and haematological improvement (HI) rates of 15%, 2% and 27%, and of 17%, 0% and 23% in the CALGB 8421 and CALGB 8921, respectively [ 123 ]. A subsequent phase III randomized trial in 191 MDS patients reported an overall response rate of 60% on the azacitidine arm (CR, 7%) compared with 5% of patients receiving supportive care; median time to leukaemic transformation or death was significantly prolonged by azacitidine (21 versus 13 months). A recent re-analysis of the three CALGB trials by applying WHO classification and International Working Group (IWG) response criteria confirmed those response figures, with 90% of patients achieving a response by six cycles; however, whereas quality of life significantly ameliorated, there was no improvement in overall survival in the whole patient population or in the separate classes of risk [ 124 ]. The combination of azacitidine with histone deacetylase inhibitors, such as sodium phenylbutyrate [ 125 ], valproic acid and all-trans retinoic acid [ 126 ], has been explored with little evidence of improvement in patients with leukaemia or high-risk MDS.

Decitabine was approved by FDA in the 2006 for the treatment of MDS on the basis of a multi-centre trial of 170 patients with intermediate-2 and high-risk international prognostic score system (IPSS) disease, randomized versus best supportive care [ 127 ]; overall response rate was 17% (CR 9%, PR 8%) with 13% of patients achieving HI. The median time to response was 3 months with a response duration of 10.3 months, although there was no difference between the two arms in time to AML or death. Significant activity at low, very well-tolerated, doses was reported [ 128 ]. Evidence of partially demethylated epigenotypes, including re-establishment of normal p15 protein expression early after drug administration, suggested pharmacologic demethylation as the therapeutic mechanism of action. Decitabine has been used also in imatinib-resistant CML [ 129 ] or in combination with imatinib in patients with accelerated or leukaemic-phase CML [ 130 ].

Vorinostat, suberoylanilide hydroxamic acid (SAHA), is an inhibitor of class I and II HDAC enzymes, and promotes cell-cycle arrest and apoptosis of cancer cells [ 131 ]; relevant target genes have been characterized through gene expression analysis [ 132 ]. Vorinostat has received FDA approval for the treatment of progressive, persistent or recurrent on, or after, two systemic therapies T-cell cutaneous lymphoma [ 133 ]. In a phase I/II study, vorinostat was used to treat 41 patients with leukaemia or MDS who were relapsed or refractory to previous therapy or who were not candidate to chemotherapy [ 134 ]. Haematologic improvement was observed in 17% of cases including two complete responses in AML. Evidence of histone H3 acetylation was found in peripheral blood and bone marrow cells, and down-regulation of proliferation-associated genes was associated with haematologic improvement [ 134 ]. A phase IIa trial with vorinostat in patients with lower-risk myelodysplastics syndromes ( NCT00486720 ) and a phase I/II trial of vorinostat in combination with azacitidine ( NCT00392353 ) are currently underway; preliminary results from phase I of the combination trial indicated that the therapy is safe and well tolerated and appears superior to azacitidine alone for time to response, overall response and CR rate [ 135 ].

The HDAC inhibitory activity of valproic acid (VPA), an antiepileptic drug, is known since 2001; VPA induces differentiation and apoptosis in malignant myeloid cell lines. Clinical activity has been demonstrated in studies in MDS patients who received VPA orally on a continuous schedule to maintain a serum concentration of 50–100 (μg/ml. The first pilot study reported a 44% overall response rate in MDS with a median response duration of 4 months [ 136 ]. In a follow-up study on 122 patients with MSD and AML an overall response rate of 20% was reported, including one CR; a higher percentage of response was observed in low-risk MDS, according to morphological subtype [ 137 ]. VPA has been used in combination with all-trans retinoic acid in patients with acute leukaemia, eventually in association with cytotoxic therapy without appreciable or with only minor improvements [ 138 – 140 ].

ITF2357 is a new synthetic HDAC class I inhibitor that possess a potent anti-proliferative and pro-apoptotic activity against cells of AML and multiple myeloma [ 141 ]. An intriguing property of HDAC inhibitors relies on their ability to down-modulate several soluble cytokines secreted by blood cells as well as from accessory cells of the bone marrow microenvironment [ 142 , 143 ]. The autocrine and paracrine secretion of different cytokines may play an important role for the neoplastic proliferation of myeloid precursor cells, and possibly represents a relevant target of new anti-neoplastic drugs. Most strikingly, ITF2357 inhibits production of IL-6, vascular endothelial growth factor (VEGF) and IFN-γ, with an IC 50 similar to that required for apoptosis induction of leukaemic cells (0.25–0.5 |μM). Despite its in vitro and in vivo anti-tumour activity, ITF2357 showed little toxicity against normal cells such as mesenchymal stem cells, hepatocytes and peripheral blood mononuclear cells (MNCs), and thrombocytopenia and gastrointestinal toxicity represent the most common side effects after its use in normal volunteers and patients [ 144 ]. Of note, similarly to other HDAC inhibitors, ITF2357 induces a significant up-regulation of the cell cycle inhibitor p21.

Because it is predicted that over 30% of human genes are regulated by microRNAs [ 145 , 146 ], and miRNAs can function either as oncosuppressors or oncogenes [ 147 ], it is easily anticipated that miRNAs and anti-miRNA drugs have great potential to be developed as a novel class of epigenetically active drugs for the treatment of cancer. Specific knockdown of miRNAs by anti-miRNA oligonucleotides (‘antagomirs’) has been pursued in vitro and in vivo . Krutzfeldt and coworkers showed for the first time the long-lasting and non-toxic silencing generated by intravenously injected antagomir in mice [ 148 ]. Inhibition of miR-122 resulted in a reduction of cholesterol levels and a decrease in hepatic fatty acids and cholesterol syntesis in normal mice and in diet-induced obese mice. Several recent papers have generated intriguing data concerning the systemic [ 149 , 150 ] or intra-tumoural injection [ 151 – 153 ] of antagomiRs, for example in the treatment of melanoma, neuroblastoma or prostate cancer xenografts, where sizeable reduction of tumour growth could be ascertained. To the best of our knowledge, there is no experience in MPNs or other haematologic disorders.

Epigenetic therapy in MPN

Only a few trials using epigenetically active drugs have been completed or are ongoing in the classic MPNs. 5-azacitidine has been used in patients with refractory/relapsed PMF and post-polycythemic/post-thrombocythemic MF in two phase II trials that differed in the drug scheduling. In the first [ 154 ], 34 patients received 5-Aza at 75 mg/m 2 daily for 7 days every 4 weeks subcutaneously (total cycle dose, 525 mg/m 2 ), while in the second trail, a 5-day weekly schedule (total dose, 375 mg/m 2 ) was employed in 10 patients [ 155 ]. Responses were classified according to the International Working Group for Myelofibrosis Research and Treatment (IWG-MRT) criteria [ 156 ]. No patient among those receiving the reduced dosage schedule achieved even a clinical improvement, the lowest response according to IWG-MRT criteria; however, only two of the 10 patients had received more than three of the six planned cycles of therapy because of toxicity, disease progression or patient choice. Of note, 75% to 90% of responses in MDS have been observed between cycles 4 and 6 of therapy respectively [ 124 ], not dissimilar from the median time of 5 months that was recorded in the higher-dose trial in MF [ 154 ]. In this study, one patient presented a partial response (3%) and clinical improvement occurred in 21% of the patients; the partial response was maintained for +22 months whereas median duration of clinical improvement was 4 months. Neutropenia was the main adverse effect with grade 3-4 severity in 29% of the patients, and thrombocytopenia all grades occurred in 9%; grade 3-4 non-neutropenic infections were reported in 26% of the patients. A kinetic analysis of global methylation of genomic DNA, measured according to a long interspersed nucleotide element (LINE) bisulphite pyrosequencing [ 157 ], demonstrated a gradual and significant decline of LINE methylation. Although changes in the extent of methylation were not significantly different between responders and non-responders, the former presented a trend towards a more rapid hypomethylating effect.

Preliminary results from a phase II multi-centre study with decitabine in 21 patients with PMF have been reported [ 158 ]. Seven patients (37%) responded, including two with blast phase-MF; there was one CR, two PR and four HI. Median time to response was two cycles and median duration of response was 5 months, with two patients maintaining their responses at + 2 and +14 months, respectively. There was a 61% reduction in the count of circulating CD34 + cells i that distinguished responders from non-responders.

The safety and efficacy of the HDAC inhibitor ITF2357 in the treatment of patients with PV, ET or MF have been evaluated in a phase II study. The rationale of the clinical trial derived from results on the in vitro activity of ITF2357 in cells from PV and ET patients carrying the JAK2V617F mutation. In these experiments, it was shown that: ( i ) cells carrying the mutated JAK2 are sensitive in colony assays to a 100- to 500-fold lower dose of ITF2357 as compared to cells bearing wild-type JAK2; ( ii ) in a classical endogenous erythroid colony (EEC) assay, ITF2357 promotes the out-growth of normal colonies over that of JAK2V617F mutated cells; ( iii ) ITF2357 induces down-modulation of JAK2V617F but not JAK2 wild-type protein in human erythroleukemia (HEL) cells, and ( iv ) that JAK2V617F inhibition takes place at the post-transcriptional level [ 159 ]. ITF2357 was evaluated in PV, ET or MF patients refractory to hydroxyurea or in younger patients who were in need of cytoreductive therapy [ 160 ]. The drug was given orally at a starting daily dose of 50 mg b.i.d. that could be escalated to 50 mg t.i.d., in the absence of toxicity. A total of 26 patients (men/women, 12/14), with a median age of 56 (range 36–70) and a confirmed diagnosis of JAK2V617F-positive PV ( n = 12), ET ( n = 1), PMF ( n = 4) or post-polycythemic/post-thrombocythemic MF ( n = 9) were enrolled in this study. In patients with PV and ET, ITF2357 was well tolerated when given up to 50 mg t.i.d. (no Grade 4 toxicity) and the haematologic response (CR+PR) was 50% at 12 weeks and 40% at 24 weeks. A rapid and sustained improvement of pruritus was observed in 80% and a reduction of splenomegaly in 50% of patients. In MF patients, the haematologic response (major, moderate and minor) was 33% and a partial response of splenomegaly was seen in 23%[ 160 ]. Based on this promising activity of ITF2357, different drug dosing and drug combinations are now under investigation.

There is a single report of vorinostat in a patient with a JAK2V617F-positive post-essential thrombocythaemia myelofibrosis who showed improvement in transfusion-dependent anaemia and thrombocytopenia [ 161 ]. Modest improvement of anaemia and reduction of transfusional support was also serendipitously observed in a patient with PMF who had received valproic acid for epilepsy prophylaxis [ 162 ]

Conclusions

In summary, although preliminary and sometimes conflicting, results of available studies support abnormal epigenetic gene regulation in MPN cells, particularly in PMF [ 163 ], as a contributing mechanism to the pathophysiology of these disorders, and maintain that epigenetics could represent a clinically relevant therapeutic target [ 163 ]. Results of the first trials with demethylating agents have been dismal, while substantial hope that HDAC inhibitors can be more effective is supported by the preliminary results of ITF2357 trial. It is also conceivable that combining epigenetic therapy with other drugs might be worthwhile and more efficacious. Gene silencing because of hypermethylation is involved in low response and resistance to drugs in solid cancers [ 164 ], and re-activation of silenced gene following decitabine was shown able to overcome resistance both in vitro and in preclinical models [ 165 , 166 ]; results of a recent dose-finding trial of decitabine with carboplatin in solid tumours hold much clinical promise. Therefore, one could imagine the opportunity to associate epigenetic therapy either with cytotoxic drugs (hydroxyurea) or with the novel, specific JAK2 inhibitors [ 163 , 167 ]. The coming years will surely witness great interest and efforts in developing effective, targeted therapy against the long-neglected MPNs.

This work was supported by Ministero della Università e Ricerca (COFIN 2006067001_003), Istituto Toscano Tumori and Ente Cassa di Risparmio di Firenze to AMV.

References

1 Swertllow SH Campo E Harris NL WHO classification of tumors of haematopoietic and lymphoid tissues 2008 Lyon International Agency for Research on Cancer

2 Dameshek W Some speculations on the myeloproliferative syndromes Blood 1951 6 372 5 14820991

3 Spivak JL Diagnosis of the myeloproliferative disorders: resolving phenotypic mimicry Semin Hematol 2003 40 1 5 12682874 10.1053/shem.2003.50026

4 Tefferi A Gangat N Wolanskyj AP 20+ yr without leukemic or fibrotic transformation in essential thrombocythemia or polycythemia vera: predictors at diagnosis Eur J Haematol 2008 80 386 90 18221390 10.1111/j.1600-0609.2008.01038.x

5 Tefferi A Thiele J Orazi A Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel Blood 2007 110 1092 7 17488875 10.1182/blood-2007-04-083501

6 James C Ugo V Le Couedic JP A unique clonal JAK2 mutation leading to constitutive signalling causes poly-cythaemia vera Nature 2005 434 1144 8 15793561 10.1038/nature03546

7 Baxter EJ Scott LM Campbell PJ Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders Lancet 2005 365 1054 61 15781101 10.1016/S0140-6736(05)71142-9

8 Levine RL Wadleigh M Cools J Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis Cancer Cell 2005 7 387 97 15837627 10.1016/j.ccr.2005.03.023

9 Kralovics R Passamonti F Buser AS A gain-of-function mutation of JAK2 in myeloproliferative disorders N Engl J Med 2005 352 1779 90 15858187 10.1056/NEJMoa051113

10 Pikman Y Lee BH Mercher T MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia PLoS Med 2006 3 e270 16834459 10.1371/journal.pmed.0030270 PMC1502153

11 Scott LM Tong W Levine RL JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis N Engl J Med 2007 356 459 68 17267906 10.1056/NEJMoa065202 PMC2873834

12 Campbell PJ Green AR The myeloproliferative disorders N Engl J Med 2006 355 2452 66 17151367 10.1056/NEJMra063728

13 Levine RL Pardanani A Tefferi A Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders Nat Rev Cancer 2007 7 673 83 17721432 10.1038/nrc2210

14 Kaushansky K The chronic myeloproliferative disorders and mutation of JAK2: Dameshek's 54 year old speculation comes of age Best Pract Res Clin Haematol 2007 20 5 12 17336249 10.1016/j.beha.2006.11.005 PMC2684109

15 Vannucchi AM Guglielmelli P Tefferi A Advances in understanding and management of myeloproliferative neoplasms CA Cancer J Clin 2009 59 171 91 19369682 10.3322/caac.20009

16 Finazzi G Barbui T Evidence and expertise in the management of polycythemia vera and essential thrombocythemia Leukemia 2008 22 1494 502 18596737 10.1038/leu.2008.177

17 Mesa RA Niblack J Wadleigh M The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients Cancer 2007 109 68 76 17123268 10.1002/cncr.22365

18 Mesa RA Verstovsek S Cervantes F Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT) Leuk Res 2007 31 737 40 17210175 10.1016/j.leukres.2006.12.002

19 Harrison CN Green AR Essential thrombocythaemia Best Pract Res Clin Haematol 2006 19 439 53 16781482 10.1016/j.beha.2005.07.004

20 Marchioli R Finazzi G Landolfi R Vascular and neoplastic risk in a large cohort of patients with polycythemia vera J Clin Oncol 2005 23 2224 32 15710945 10.1200/JCO.2005.07.062

21 Tefferi A Primary myelofibrosis Cancer Treat Res 2008 142 29 49 18283781

22 Finazzi G Caruso V Marchioli R Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study Blood 2005 105 2664 70 15585653 10.1182/blood-2004-09-3426

23 Finazzi G Barbui T Risk-adapted therapy in essential thrombocythemia and polycythemia vera Blood Rev 2005 19 243 52 15963833 10.1016/j.blre.2005.01.001

24 Berk PD Goldberg JD Donovan PB Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols Semin Hematol 1986 23 132 43 3704665

25 Policitemia GIS Polycythemia vera: the natural history of 1213 patients followed for 20 years. Gruppo Italiano Studio Policitemia Ann Intern Med 1995 123 656 64 7574220 10.7326/0003-4819-123-9-199511010-00003

26 Landolfi R Marchioli R Kutti J Efficacy and safety of low-dose aspirin in polycythemia vera N Engl J Med 2004 350 114 24 14711910 10.1056/NEJMoa035572

27 Fruchtman SM Mack K Kaplan ME From efficacy to safety: a Polycythemia Vera Study group report on hydroxyurea in patients with polycythemia vera Semin Hematol 1997 34 17 23 9025158

28 Cortelazzo S Finazzi G Ruggeri M Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis N Engl J Med 1995 332 1132 6 7700286 10.1056/NEJM199504273321704

29 Harrison CN Campbell PJ Buck G Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia N Engl J Med 2005 353 33 45 16000354 10.1056/NEJMoa043800

30 Passamonti F Rumi E Pungolino E Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia Am J Med 2004 117 755 61 15541325 10.1016/j.amjmed.2004.06.032

31 Berk PD Goldberg JD Silverstein MN Increased incidence of acute leukemia in polycythemia vera associated with chlorambucil therapy N Engl J Med 1981 304 441 7 7005681 10.1056/NEJM198102193040801

32 Barosi G Myelofibrosis with myeloid metaplasia Hematol Oncol Clin North Am 2003 17 1211 26 14560783 10.1016/s0889-8588(03)00080-7

33 Cervantes F Passamonti F Barosi G Life expectancy and prognostic factors in the classic BCR/ABL-negative myeloproliferative disorders Leukemia 2008 22 905 14 18385755 10.1038/leu.2008.72

34 Cervantes F Dupriez B Pereira A A new prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment Blood 2008 113 2895 901 18988864 10.1182/blood-2008-07-170449

35 Kroger N Mesa RA Choosing between stem cell therapy and drugs in myelofibrosis Leukemia 2008 22 474 86 18185525 10.1038/sj.leu.2405080

36 Jones AV Silver RT Waghorn K Minimal molecular response in polycythemia vera patients treated with imatinib or interferon alpha Blood 2006 107 3339 41 16352805 10.1182/blood-2005-09-3917

37 Kiladjian JJ Chomienne C Fenaux P Interferon-alpha therapy in bcr-abl-negative myeloproliferative neoplasms Leukemia 2008 22 1990 8 18843285 10.1038/leu.2008.280

38 Kiladjian JJ Cassinat B Chevret S Pegylated Interferon-alfa-2a induces complete hematological and molecular responses with low toxicity in polycythemia vera Blood 2008 112 3065 72 18650451 10.1182/blood-2008-03-143537

39 Kundrapu K Colenberg L Duhe RJ Activation loop tyrosines allow the JAK2(V617F) mutant to attain hyperactivation Cell Biochem Biophys 2008 52 103 12 18841497 10.1007/s12013-008-9025-4

40 Vainchenker W Constantinescu SN A unique activating mutation in JAK2 (V617F) is at the origin of polycythemia vera and allows a new classification of myeloproliferative diseases Hematology Am Soc Hematol Educ Program 2005 195 200 16304380 10.1182/asheducation-2005.1.195

41 Wernig G Mercher T Okabe R Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model Blood 2006 107 4274 81 16478879 10.1182/blood-2005-12-4824 PMC1895786

42 Lacout C Pisani DF Tulliez M JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis Blood 2006 108 1652 60 16670266 10.1182/blood-2006-02-002030

43 Bumm TG Elsea C Corbin AS Characterization of murine JAK2V617F-positive myeloproliferative disease Cancer Res 2006 66 11156 65 17145859 10.1158/0008-5472.CAN-06-2210

44 Zaleskas VM Krause DS Lazarides K Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F PLoS ONE 2006 1 e18 17183644 10.1371/journal.pone.0000018 PMC1762384

45 Tiedt R Hao-Shen H Sobas MA Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice Blood 2008 111 3931 40 18160670 10.1182/blood-2007-08-107748

46 Shide K Shimoda HK Kumano T Development of ET, primary myelofibrosis and PV in mice expressing JAK2 V617F Leukemia 2007 22 87 95 10.1038/sj.leu.2405043 18033315

47 Verstovsek S Silver RT Cross NC JAK2V617F mutational frequency in polycythemia vera: 100%, >90%, less? Leukemia 2006 20 2067 16990780 10.1038/sj.leu.2404379

48 Vizmanos JL Ormazabal C Larrayoz MJ JAK2 V617F mutation in classic chronic myeloproliferative diseases: a report on a series of 349 patients Leukemia 2006 20 534 5 16408096 10.1038/sj.leu.2404086

49 Szpurka H Tiu R Murugesan G Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T), another myeloproliferative condition characterized by JAK2 V617F mutation Blood 2006 108 2173 81 16741247 10.1182/blood-2006-02-005751 PMC1895556

50 Renneville A Quesnel B Charpentier A High occurrence of JAK2 V617 mutation in refractory anemia with ringed sideroblasts associated with marked thrombocytosis Leukemia 2006 20 2067 70 16990759 10.1038/sj.leu.2404405

51 Pietra D Li S Brisci A Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders Blood 2007 111 1686 9 17984312 10.1182/blood-2007-07-101576

52 Pardanani AD Levine RL Lasho T MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients Blood 2006 108 3472 6 16868251 10.1182/blood-2006-04-018879

53 Guglielmelli P Pancrazzi A Bergamaschi G Anaemia characterises patients with myelofibrosis harbouring Mpl mutation Br J Haematol 2007 137 244 7 17408465 10.1111/j.1365-2141.2007.06565.x

54 Beer PA Campbell P Scott LM MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort Blood 2008 112 141 9 18451306 10.1182/blood-2008-01-131664

55 Vannucchi AM Antonioli E Guglielmelli P Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia Blood 2008 112 844 7 18519816 10.1182/blood-2008-01-135897

56 Chaligne R Tonetti C Besancenot R New mutations of MPL in primitive myelofibrosis: only the MPL W515 mutations promote a G(1)/S-phase transition Leukemia 2008 22 1557 66 18528423 10.1038/leu.2008.137

57 Lasho TL Pardanani A McClure RF Concurrent MPL515 and JAK2V617F mutations in myelofibrosis: chronology of clonal emergence and changes in mutant allele burden over time Br J Haematol 2006 135 683 7 17107350 10.1111/j.1365-2141.2006.06348.x

58 James C The JAK2V617F Mutation in polycythemia vera and other myeloproliferative disorders: one mutation for three diseases? Hematology Am Soc Hematol Educ Program 2008 2008 69 75 19074061 10.1182/asheducation-2008.1.69

59 Vannucchi AM Guglielmelli P Molecular pathophysiology of Philadelphia-negative myeloproliferative disorders: beyond JAK2 and MPL mutations Haematologica 2008 93 972 6 18591622 10.3324/haematol.13266

60 Skoda R The genetic basis of myeloproliferative disorders Hematology Am Soc Hematol Educ Program 2007 2007 1 10 18024602 10.1182/asheducation-2007.1.1

61 Nussenzveig RH Swierczek SI Jelinek J Polycythemia vera is not initiated by JAK2V617F mutation Exp Hematol 2007 35 32 8 17198871 10.1016/j.exphem.2006.11.012

62 Delhommeau F Dupont S James C TET2 is a novel tumor suppressor gene inactivated in myeloproliferative neoplasms: identification of a pre-JAK2 V617F event Blood 2008 112 lba 3A

63 Pardanani A Fridley BL Lasho TL Host genetic variation contributes to phenotypic diversity in myeloproliferative disorders Blood 2008 111 2785 9 18006699 10.1182/blood-2007-06-095703

64 Campbell PJ Scott LM Buck G Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study Lancet 2005 366 1945 53 16325696 10.1016/S0140-6736(05)67785-9

65 Holliday R The inheritance of epigenetic defects Science 1987 238 163 70 3310230 10.1126/science.3310230

66 Jenuwein T Allis CD Translating the histone code Science 2001 293 1074 80 11498575 10.1126/science.1063127

67 Kondo Y Shen L Cheng AS Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation Nat Genet 2008 40 741 50 18488029 10.1038/ng.159

68 Esteller M Epigenetics in cancer N Engl J Med 2008 358 1148 59 18337604 10.1056/NEJMra072067

69 Esteller M Cancer epigenomics: DNA methylomes and histone-modification maps Nat Rev 2007 8 286 98 10.1038/nrg2005 17339880

70 Esteller M Epigenetic gene silencing in cancer: the DNA hypermethylome Hum Mol Genet 2007 16 50 9 17613547 10.1093/hmg/ddm018

71 Lund AH van Lohuizen M Epigenetics and cancer Genes Dev 2004 18 2315 35 15466484 10.1101/gad.1232504

72 Weber M Davies JJ Wittig D Chromosome-wide and promoter-specific analyses identify sites of differential DNA methylation in normal and transformed human cells Nat Genet 2005 37 853 62 16007088 10.1038/ng1598

73 Eden A Gaudet F Waghmare A Chromosomal instability and tumors promoted by DNA hypomethylation Science 2003 300 455 12702868 10.1126/science.1083557

74 Gaudet F Hodgson JG Eden A Induction of tumors in mice by genomic hypomethylation Science 2003 300 489 92 12702876 10.1126/science.1083558

75 Xu GL Bestor TH Bourc’his D Chromosome instability and immunodeficiency syndrome caused by mutations in a DNA methyltransferase gene Nature 1999 402 187 91 10647011 10.1038/46052

76 Herman JG Baylin SB Gene silencing in cancer in association with promoter hypermethylation N Engl J Med 2003 349 2042 54 14627790 10.1056/NEJMra023075

77 Esteller M Corn PG Baylin SB A gene hypermethylation profile of human cancer Cancer Res 2001 61 3225 9 11309270

78 Bachman KE Herman JG Corn PG Methylation-associated silencing of the tissue inhibitor of metalloproteinase-3 gene suggest a suppressor role in kidney, brain, and other human cancers Cancer Res 1999 59 798 802 10029065

79 Jones PA Baylin SB The fundamental role of epigenetic events in cancer Nat Rev 2002 3 415 28 10.1038/nrg816 12042769

80 Cameron EE Bachman KE Myohanen S Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer Nat Genet 1999 21 103 7 9916800 10.1038/5047

81 Bartel DP MicroRNAs: genomics, biogenesis, mechanism, and function Cell 2004 116 281 97 14744438 10.1016/s0092-8674(04)00045-5

82 Ambros V Chen X The regulation of genes and genomes by small RNAs Development 2007 134 1635 41 17409118 10.1242/dev.002006

83 Lim LP Lau NC Garrett-Engele P Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs Nature 2005 433 769 73 15685193 10.1038/nature03315

84 Calin GA Croce CM MicroRNA signatures in human cancers Nat Rev Cancer 2006 6 857 66 17060945 10.1038/nrc1997

85 Johnson SM Grosshans H Shingara J RAS is regulated by the let-7 microRNA family Cell 2005 120 635 47 15766527 10.1016/j.cell.2005.01.014

86 Cimmino A Calin GA Fabbri M miR-15 and miR-16 induce apoptosis by targeting BCL2 Proc Natl Acad Sci USA 2005 102 13944 9 16166262 10.1073/pnas.0506654102 PMC1236577

87 Garzon R Croce CM MicroRNAs in normal and malignant hematopoiesis Curr Opin Hematol 2008 15 352 8 18536574 10.1097/MOH.0b013e328303e15d

88 Zhao H Kalota A Jin S The c-myb protooncogene and microRNA (miR)-15a comprise an active autoregulatory feedback loop in human hematopoietic cells Blood 2008 113 505 16 18818396 10.1182/blood-2008-01-136218 PMC2628359

89 Fazi F Rosa A Fatica A A minicircuitry comprised of microRNA-223 and transcription factors NFI-A and C/EBPalpha regulates human granu-lopoiesis Cell 2005 123 819 31 16325577 10.1016/j.cell.2005.09.023

90 Weber B Stresemann C Brueckner B Methylation of human microRNA genes in normal and neoplastic cells Cell Cycle 2007 6 1001 5 17457051 10.4161/cc.6.9.4209

91 Lujambio A Ropero S Ballestar E Genetic unmasking of an epigenetically silenced microRNA in human cancer cells Cancer Res 2007 67 1424 9 17308079 10.1158/0008-5472.CAN-06-4218

92 Varambally S Cao Q Mani RS Genomic loss of microRNA-101 leads to overexpression of histone methyltrans-ferase EZH2 in cancer Science 2008 322 1695 9 19008416 10.1126/science.1165395 PMC2684823

93 Opalinska J Sohal D Parmar S A high resolution epigenomic map of myelofibrosis reveals multiple chromosomal deletions and amplifications accompanied by a high level of functionally important methylation Blood 2006 110 2120A

94 Wang JC Chen C Dumlao T Enhanced histone deacethylase enzyme activity in primary myelofibrosis Leuk Lymph 2008 49 2321 7 10.1080/10428190802527699 19052980

95 Valentino L Pierre J JAK/STAT signal transduction: regulators and implication in hematological malignancies Biochem Pharmacol 2006 71 713 21 16426581 10.1016/j.bcp.2005.12.017

96 Hookham MB Elliott J Suessmuth Y The myeloproliferative disorder-associated JAK2 V617F mutant escapes negative regulation by suppressor of cytokine signaling 3 Blood 2007 109 4924 9 17317861 10.1182/blood-2006-08-039735

97 Kishimoto T Kikutani H Knocking the SOCS off a tumor suppressor Nat Genet 2001 28 4 5 11326261 10.1038/88244

98 Liu TC Lin SF Chang JG Epigenetic alteration of the SOCS1 gene in chronic myeloid leukaemia Brit J Haematol 2003 123 645 61 10.1046/j.1365-2141.2003.04660.x 14616969

99 Roman-Gomez J Jimenez-Velasco A Castillejo JA The suppressor of cytokine signaling-1 is constitutively expressed in chronic myeloid leukemia and correlates with poor cytogenetic response to interferon-alpha Haematologica 2004 89 42 8 14754605

100 Teofili L Martini M Cenci T Epigenetic alteration of SOCS family members is a possible pathogenetic mechanism in JAK2 wild type myeloproliferative diseases Int J Cancer 2008 123 1586 92 18623127 10.1002/ijc.23694

101 Fourouclas N Li J Gilby DC Methylation of the suppressor of cytokine signaling 3 gene (SOCS3) in myeloproliferative disorders Haematologica 2008 93 1635 44 18815196 10.3324/haematol.13043

102 Capello D Deambrogi C Rossi D Epigenetic inactivation of suppressors of cytokine signalling in Philadelphia-negative chronic myeloproliferative disorders Br J Haematol 2008 141 504 11 18318760 10.1111/j.1365-2141.2008.07072.x

103 Fernandez-Mercado M Cebrian V Euba B Methylation status of SOCS1 and SOCS3 in BCR-ABL negative and JAK2V617F negative chronic myeloproliferative neoplasms Leuk Res 2008 32 1638 40 18440067 10.1016/j.leukres.2008.03.014

104 Chen CY Tsay W Tang JL SOCS1 methylation in patients with newly diagnosed acute myeloid leukemia Genes Chrom Canc 2003 37 300 5 10.1002/gcc.10222 12759928

105 Watanabe D Ezoe S Fujimoto M Suppressor of cytokine signalling-1 gene silencing in acute myeloid leukaemia and human haematopoietic cell lines Br J Haematol 2004 126 726 35 15327527 10.1111/j.1365-2141.2004.05107.x

106 Hatirnaz O Ure U Ar C The SOCS-1 gene methylation in chronic myeloid leukemia patients Am J Hematol 2007 82 729 30 17315216 10.1002/ajh.20886

107 Wu SJ Yao M Chou WC Clinical implications of SOCS1 methylation in myelodysplastic syndrome Br J Haematol 2006 135 317 23 16978223 10.1111/j.1365-2141.2006.06293.x

108 Jost E do ON Dahl E Epigenetic alterations complement mutation of JAK2 tyrosine kinase in patients with BCR/ABL-negative myeloproliferative disorders Leukemia 2007 21 505 10 17230231 10.1038/sj.leu.2404513

109 Temerinac S Klippel S Strunck E Cloning of PRV-1, a novel member of the uPAR receptor superfamily which is over-expressed in polycythemia rubra vera Blood 2000 95 2569 76 10753836

110 Jelinek J Li J Mnjoyan Z Epigenetic control of PRV-1 expression on neutrophils Exp Hematol 2007 35 1677 83 17976520 10.1016/j.exphem.2007.09.008

111 Barosi G Viarengo G Pecci A Diagnostic and clinical relevance of the number of circulating CD34(+) cells in myelofibrosis with myeloid metaplasia Blood 2001 98 3249 55 11719361 10.1182/blood.v98.12.3249

112 Guglielmelli P Zini R Bogani C Molecular profiling of CD34+ cells in idiopathic myelofibrosis identifies a set of disease-associated genes and reveals the clinical significance of Wilms’ tumor gene 1 (WT1) Stem Cells 2007 25 165 73 16990584 10.1634/stemcells.2006-0351

113 Rosti V Massa M Vannucchi AM The expression of CXCR4 is down-regulated on the CD34+ cells of patients with myelofibrosis with myeloid metaplasia Blood Cells Mol Dis 2007 38 280 6 17350297 10.1016/j.bcmd.2007.01.003

114 Bogani C Ponziani V Guglielmelli P Hypermethylation of CXCR4 promoter in CD34+ cells from patients with primary myelofibrosis Stem Cells 2008 26 1920 30 18511598 10.1634/stemcells.2008-0377

115 Shi J Zhao Y Ishii T Effects of chromatin-modifying agents on CD34+ cells from patients with idiopathic myelofibrosis Cancer Res 2007 67 6417 24 17616702 10.1158/0008-5472.CAN-07-0572

116 Wang X Zhang W Ishii T Correction of the abnormal trafficking of primary myelofibrosis CD34+ cells by treatment with chromatin modifying agents Blood 2008 112 101A 10.1158/0008-5472.CAN-09-1823 PMC3234420 19752087

117 Shi S Calhoun HC Xia F JAK signaling globally counteracts heterochro-matic gene silencing Nat Genet 2006 38 1071 6 16892059 10.1038/ng1860 PMC3092431

118 Zhang Q Wang HY Woetmann A STAT3 induces transcription of the DNA methyltransferase 1 gene (DNMT1) in malignant T lymphocytes Blood 2006 108 1058 64 16861352 10.1182/blood-2005-08-007377 PMC1895864

119 Guglielmelli P Tozzi L Pancrazzi A MicroRNA expression profile in granulocytes from primary myelofibrosis patients Exp Hematol 2007 35 1708 18 17976522 10.1016/j.exphem.2007.08.020

120 Bruchova H Merkerova M Prchal JT Aberrant expression of microRNA in polycythemia vera Haematologica 2008 93 1009 16 18508790 10.3324/haematol.12706

121 Bruchova H Yoon D Agarwal AM Regulated expression of microRNAs in normal and polycythemia vera erythropoiesis Exp Hematol 2007 35 1657 67 17976518 10.1016/j.exphem.2007.08.021 PMC2699372

122 O’Connor OA Heaney ML Schwartz L Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies J Clin Oncol 2006 24 166 73 16330674 10.1200/JCO.2005.01.9679

123 Silverman LR Holland JF Weinberg RS Effects of treatment with 5-azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes Leukemia 1993 7 21 9 7683352

124 Silverman LR McKenzie DR Peterson BL Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B J Clin Oncol 2006 24 3895 903 16921040 10.1200/JCO.2005.05.4346

125 Maslak P Chanel S Camacho LH Pilot study of combination transcriptional modulation therapy with sodium phenyl-butyrate and 5-azacytidine in patients with acute myeloid leukemia or myelodysplastic syndrome Leukemia 2006 20 212 7 16357841 10.1038/sj.leu.2404050

126 Soriano AO Yang H Faderl S Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome Blood 2007 110 2302 8 17596541 10.1182/blood-2007-03-078576

127 Kantarjian H Issa JP Rosenfeld CS Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study Cancer 2006 106 1794 803 16532500 10.1002/cncr.21792

128 Kantarjian H Oki Y Garcia-Manero G Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia Blood 2007 109 52 7 16882708 10.1182/blood-2006-05-021162

129 Issa JP Gharibyan V Cortes J Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate J Clin Oncol 2005 23 3948 56 15883410 10.1200/JCO.2005.11.981

130 Oki Y Kantarjian HM Gharibyan V Phase II study of low-dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia Cancer 2007 109 899 906 17236224 10.1002/cncr.22470

131 Marks PA Breslow R Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug Nat Biotechnol 2007 25 84 90 17211407 10.1038/nbt1272

132 Peart MJ Smyth GK van Laar RK Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors Proc Natl Acad Sci USA 2005 102 3697 702 15738394 10.1073/pnas.0500369102 PMC552783

133 Khan O La Thangue NB Drug insight: histone deacetylase inhibitor-based therapies for cutaneous T-cell lymphomas Nature Clin Pract 2008 5 714 26 10.1038/ncponc1238 18839006

134 Garcia-Manero G Yang H Bueso-Ramos C Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes Blood 2008 111 1060 6 17962510 10.1182/blood-2007-06-098061

135 Silverman LR Verma A Odchimar-Reissig R A phase I/II study of vorinostat, an oral histone deacethylase inhibitor, in combination with azacitidine in patients with the myelodysplastic syndromes and acute myeloid leukemia (AML). Initial results of the phase I trial: a New York Cancer Consortium J Clin Oncol 2008 26 7000A

136 Kuendgen A Strupp C Aivado M Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid Blood 2004 104 1266 9 15155466 10.1182/blood-2003-12-4333

137 Kuendgen A Gattermann N Valproic acid for the treatment of myeloid malignancies Cancer 2007 110 943 54 17647267 10.1002/cncr.22891

138 Raffoux E Chaibi P Dombret H Valproic acid and all-trans retinoic acid for the treatment of elderly patients with acute myeloid leukemia Haematologica 2005 90 986 8 15996941

139 Pilatrino C Cilloni D Messa E Increase in platelet count in older, poor-risk patients with acute myeloid leukemia or myelodysplastic syndrome treated with valproic acid and all-trans retinoic acid Cancer 2005 104 101 9 15895376 10.1002/cncr.21132

140 Bug G Ritter M Wassmann B Clinical trial of valproic acid and all-trans retinoic acid in patients with poor-risk acute myeloid leukemia Cancer 2005 104 2717 25 16294345 10.1002/cncr.21589

141 Golay J Cuppini L Leoni F The histone deacetylase inhibitor ITF2357 has anti-leukemic activity in vitro and in vivo and inhibits IL-6 and VEGF production by stromal cells Leukemia 2007 21 1892 900 17637810 10.1038/sj.leu.2404860

142 Leoni F Zaliani A Bertolini G The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antiinflammatory properties via suppression of cytokines Proc Natl Acad Sci USA 2002 99 2995 3000 11867742 10.1073/pnas.052702999 PMC122461

143 Carta S Tassi S Semino C Histone deacetylase inhibitors prevent exocytosis of interleukin-1beta-containing secretory lysosomes: role of microtubules Blood 2006 108 1618 26 16684958 10.1182/blood-2006-03-014126 PMC1895509

144 Galli M Salmoiraghi S Golay J A phase II multiple dose clinical trial of histone deacetylase inhibitor ITF2357 in patients with relapsed or progressive multiple myeloma: preliminary results Blood 2007 110 1175A 10.1007/s00277-009-0793-8 19633847

145 Miranda KC Huynh T Tay Y A pattern-based method for the identification of MicroRNA binding sites and their corresponding heteroduplexes Cell 2006 126 1203 17 16990141 10.1016/j.cell.2006.07.031

146 Zhang B Wang Q Pan X MicroRNAs and their regulatory roles in animals and plants J Cell Physiol 2007 210 279 89 17096367 10.1002/jcp.20869

147 Zhang B Pan X Cobb GP microRNAs as oncogenes and tumor suppressors Dev Biol 2007 302 1 12 16989803 10.1016/j.ydbio.2006.08.028

148 Krutzfeldt J Rajewsky N Braich R Silencing of microRNAs in vivo with ‘antagomirs’ Nature 2005 438 685 9 16258535 10.1038/nature04303

149 Krutzfeldt J Kuwajima S Braich R Specificity, duplex degradation and subcellular localization of antagomirs Nucleic Acids Res 2007 35 2885 92 17439965 10.1093/nar/gkm024 PMC1888827

150 Care A Catalucci D Felicetti F MicroRNA-133 controls cardiac hypertrophy Nat Med 2007 13 613 8 17468766 10.1038/nm1582

151 Felicetti F Errico MC Bottero L The promyelocytic leukemia zinc finger-microRNA-221/-222 pathway controls melanoma progression through multiple oncogenic mechanisms Cancer Res 2008 68 2745 54 18417445 10.1158/0008-5472.CAN-07-2538

152 Fontana L Fiori ME Albini S Antagomir-17–5p abolishes the growth of therapy-resistant neuroblastoma through p21 and BIM PLoS ONE 2008 3 e2236 18493594 10.1371/journal.pone.0002236 PMC2375057

153 Mercatelli N Coppola V Bonci D The inhibition of the highly expressed miR-221 and miR-222 impairs the growth of prostate carcinoma xenografts in mice PLoS ONE 2008 3 e4029 19107213 10.1371/journal.pone.0004029 PMC2603596

154 Quintas-Cardama A Tong W Kantarjian H A phase II study of 5-azacitidine for patients with primary and post-essential thrombocythemia/polycythemia vera myelofibrosis Leukemia 2008 22 965 70 18385750 10.1038/leu.2008.91 PMC4369783

155 Mesa RA Verstovsek S Rivera C 5-Azacitidine has limited therapeutic activity in myelofibrosis Leukemia 2008 23 180 2 18509350 10.1038/leu.2008.136 PMC8721528

156 Tefferi A Barosi G Mesa RA International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT) Blood 2006 108 1497 503 16675707 10.1182/blood-2006-03-009746

157 Yang AS Estecio MR Doshi K A simple method for estimating global DNA methylation using bisulfite PCR of repetitive DNA elements Nucleic Acids Res 2004 32 e38 14973332 10.1093/nar/gnh032 PMC373427

158 Odenike OM Godwin JE Van Besien K Phase II trial of low dose, subcutaneous decitabine in myelofibrosis Blood 2008 112 2809A 10.1182/bloodadvances.2024013215 PMC11599980 39250708

159 Guerini V Barbui V Spinelli O The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2(V617F) Leukemia 2008 22 740 7 18079739 10.1038/sj.leu.2405049

160 Rambaldi A Dellacasa CM Salmoiraghi S A phase 2A study of the histone-deacetylase inhibitor ITF2357 in patients with Jak2V617F positive chronic myeloproliferative neoplasms Blood 2008 112 100A 20560970 10.1111/j.1365-2141.2010.08266.x

161 Lee J Clinical efficacy of vorinostat in a patient with essential thrombocytosis and subsequent myelofibrosis Ann Hematol 2008 88 699 700 19030859 10.1007/s00277-008-0640-3

162 Inoue Y Suzuki T Takimoto M Treatment with valproic acid for myelofibrosis with myeloid metaplasia Ann Hematol 2005 84 833 4 16132902 10.1007/s00277-005-1104-7

163 Rambaldi A Barbui T Barosi G From palliation to epigenetic therapy in myelofibrosis Hematology Am Soc Hematol Educ Program 2008 2008 83 91 19074063 10.1182/asheducation-2008.1.83

164 Plumb JA Strathdee G Sludden J Reversal of drug resistance in human tumor xenografts by 2’-deoxy-5-azacyti-dine-induced demethylation of the hMLH1 gene promoter Cancer Res 2000 60 6039 44 11085525

165 Reu FJ Bae SI Cherkassky L Overcoming resistance to interferon-induced apoptosis of renal carcinoma and melanoma cells by DNA demethylation J Clin Oncol 2006 24 3771 9 16801630 10.1200/JCO.2005.03.4074

166 Reu FJ Leaman DW Maitra RR Expression of RASSF1A, an epigenetically silenced tumor suppressor, overcomes resistance to apoptosis induction by interferons Cancer Res 2006 66 2785 93 16510600 10.1158/0008-5472.CAN-05-2303 PMC1769551

167 Pardanani A JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials Leukemia 2008 22 23 30 17882282 10.1038/sj.leu.2404948

168 Aviram A Witenberg B Shaklai M Detection of methylated ABL1 promoter in philadelphia-negative myeloproliferative disorders Blood Cells Mol Dis 2003 30 100 6 12667992 10.1016/s1079-9796(03)00015-9

169 Ihalainen J Juvonen E Savolainen ER Calcitonin gene methylation in chronic myeloproliferative disorders Leukemia 1994 8 230 5 8309247

170 Kumagai T Tefferi A Jones L Methylation analysis of the cell cycle control genes in myelofibrosis with myeloid metaplasia Leuk Res 2005 29 511 5 15755503 10.1016/j.leukres.2004.11.002

171 Wang JC Chen W Nallusamy S Hypermethylation of the P15INK4b and P16INK4a in agnogenic myeloid metaplasia (AMM) and AMM in leukaemic transformation Br J Haematol 2002 116 582 6 11849214 10.1046/j.0007-1048.2001.03319.x

172 Oki Y Jelinek J Beran M Mutations and promoter methylation status of NPM1 in myeloproliferative disorders Haematologica 2006 91 1147 8 16870548

173 Jones LC Tefferi A Idos GE RARbeta2 is a candidate tumor suppressor gene in myelofibrosis with myeloid metaplasia Oncogene 2004 23 7846 53 15361842 10.1038/sj.onc.1207510

174 Hemavathy KC Chang TH Zhang H Reduced expression of TGF beta1RII in agnogenic myeloid metaplasia is not due to mutation or methylation Leuk Res 2006 30 47 53 16054691 10.1016/j.leukres.2005.06.010

175 Li J Bench AJ Huntly BJ Mutation and methylation analysis of the transforming growth factor beta receptor II gene in polycythaemia vera Br J Haematol 2001 115 872 80 11843821 10.1046/j.1365-2141.2001.03215.x